Business Context and Reporting Period
Oculis Holding AG is a global late clinical-stage biopharmaceutical company headquartered in Zug, Switzerland, with operations in the U.S., Iceland, France, and Hong Kong. The company focuses on developing innovative therapeutics for ophthalmic and neuro-ophthalmic diseases. This summary covers the fiscal year ended December 31, 2025, as reported in the Form 20-F Annual Report.
The company has no products approved for commercial sale and has not generated revenue from product sales. Its pipeline consists of three primary clinical-stage candidates: OCS-01 (topical treatment for Diabetic Macular Edema), Licaminlimab (treatment for Dry Eye Disease), and Privosegtor (neuroprotective agent for Optic Neuritis and NAION).
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 (CHF) | 2024 (CHF) |
|---|---|---|
| Revenue | 0 | 0 |
| Grant Income | 1.2 million | 0.7 million |
| Net Loss | (99.0 million) | (85.8 million) |
| Operating Loss | (81.7 million) | (73.2 million) |
| Research & Development Expenses | (57.1 million) | (52.1 million) |
| General & Administrative Expenses | (25.8 million) | (21.8 million) |
| Cash, Cash Equivalents & Short-Term Investments | 213.0 million | 98.7 million |
| Accumulated Losses | (384.5 million) | (285.6 million) |
| Outstanding Ordinary Shares | 57,984,438 | 44,662,402 |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by 15.4% to CHF 99.0 million, driven by higher operating expenses and a foreign currency exchange loss of CHF 6.1 million (compared to a gain of CHF 1.3 million in 2024).
- R&D Expenses: Increased by 9.6% to CHF 57.1 million. This was primarily due to advancements in the Privosegtor program and the OCS-01 DIAMOND Phase 3 trials. Costs for Licaminlimab decreased as the Phase 2 RELIEF trial concluded in 2024.
- Liquidity Position: Cash and short-term investments more than doubled to CHF 213.0 million, fueled by two major equity offerings in 2025 (February and November) totaling approximately CHF 179 million in net proceeds.
- Warrant Liabilities: The fair value adjustment on warrant liabilities resulted in a loss of CHF 12.3 million in 2025, down from CHF 15.5 million in 2024, though the liability balance decreased to CHF 14.5 million due to warrant exercises.
Guidance, Outlook, and Management Commentary
- Clinical Milestones:
- OCS-01: Enrollment for the pivotal DIAMOND-1 and DIAMOND-2 Phase 3 trials in Diabetic Macular Edema (DME) was completed in April 2025. Topline results are expected in Q2 2026.
- Licaminlimab: The PREDICT-1 registrational Phase 2/3 trial for Dry Eye Disease (DED) using a genotype-based approach was initiated in Q4 2025. Topline results are expected in Q4 2026.
- Privosegtor: The PIONEER registrational program for Optic Neuritis (ON) and NAION was initiated in Q4 2025. The company plans to submit an IND for Multiple Sclerosis (MS) relapses in 2026.
- Liquidity Outlook: Management believes existing cash resources (CHF 213.0 million) are sufficient to fund operations for at least the next 12 months without additional financing or drawing on the loan facility.
- Debt Facility: In July 2025, the company amended its loan facility with Kreos Capital (BlackRock) to provide up to CHF 75.0 million (potentially CHF 100.0 million) in borrowing capacity. No amounts were drawn as of year-end. The facility includes an amended warrant for up to 494,259 shares.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the complexity of regulatory approvals (specifically the Section 505(b)(2) pathway for OCS-01), reliance on third-party manufacturers, and the need for future capital to sustain operations beyond the current runway.
Investor Verification Checklist
- Clinical Trial Readouts: Verify the timing and results of the OCS-01 DIAMOND trials (expected Q2 2026) and Licaminlimab PREDICT-1 trial (expected Q4 2026), as these are critical value drivers.
- Regulatory Pathway for OCS-01: Confirm the FDA's stance on the Section 505(b)(2) approval pathway, as failure to utilize this could significantly delay approval and increase costs.
- Cash Burn Rate: Monitor quarterly cash burn to ensure the "12-month runway" estimate remains valid given the high costs of late-stage clinical trials.
- Warrant Exercises: Track the exercise of outstanding BCA Public and Private Warrants (exercise price $11.50) and the BlackRock Warrant, as these impact dilution and cash inflows.
- License Milestones: Review upcoming milestone payment obligations to Accure Therapeutics (Privosegtor) and Novartis (Licaminlimab), which could trigger significant cash outflows upon regulatory or commercial success.